Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersen.
Saved in:
| Title: | Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersen. |
|---|---|
| Authors: | Fontana M; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London, United Kingdom., Ambardekar AV; Department of Medicine, Division of Cardiology, University of Colorado, Aurora, CO, USA., Cappelli F; Tuscan Regional Amyloidosis Center, Department of Clinical and Experimental Medicine, Careggi University Hospital, Florence, Italy., Cuddy SAM; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA., Davis MK; Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada., Garcia-Pavia P; Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHIM, CIBERCV, and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain., Hanna M; Amyloidosis Center, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA., Khouri MG; Department of Medicine, Division of Cardiology, Duke University Hospital System, Durham, NC, USA., Masri A; Division of Cardiovascular Medicine, Oregon Health and Sciences University, Portland, OR, USA., Maurer MS; Columbia University Irving Medical Center, New York, NY, USA., Obici L; Amyloidosis Research and Treatment Centre, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy., Solomon S; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA., Sperry BW; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA., Tahara N; Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume, Japan., Waddington-Cruz M; Centro de Paramiloidose Antônio Rodrigues de Mello (CEPARM), Amyloidosis Center, University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; Amyloidosis Center, Complexo Hospitalar Américas- Samaritano-Vitória, Barra da Tijuca, Rio de Janeiro, Brazil., Conrad T; Statistics, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Rockville, MD, USA., Yang Q; Ionis Pharmaceuticals, Carlsbad, CA, USA., Chen J; Late-Stage Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MA, USA., Tsimikas S; Ionis Pharmaceuticals, Carlsbad, CA, USA., Gillmore JD; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London, United Kingdom. |
| Source: | European journal of heart failure [Eur J Heart Fail] 2026 May 30. Date of Electronic Publication: 2026 May 30. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 100887595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0844 (Electronic) Linking ISSN: 13889842 NLM ISO Abbreviation: Eur J Heart Fail Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42217207 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersen. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Fontana+M%22">Fontana M</searchLink>; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Ambardekar+AV%22">Ambardekar AV</searchLink>; Department of Medicine, Division of Cardiology, University of Colorado, Aurora, CO, USA.<br /><searchLink fieldCode="AU" term="%22Cappelli+F%22">Cappelli F</searchLink>; Tuscan Regional Amyloidosis Center, Department of Clinical and Experimental Medicine, Careggi University Hospital, Florence, Italy.<br /><searchLink fieldCode="AU" term="%22Cuddy+SAM%22">Cuddy SAM</searchLink>; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Davis+MK%22">Davis MK</searchLink>; Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.<br /><searchLink fieldCode="AU" term="%22Garcia-Pavia+P%22">Garcia-Pavia P</searchLink>; Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHIM, CIBERCV, and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Hanna+M%22">Hanna M</searchLink>; Amyloidosis Center, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.<br /><searchLink fieldCode="AU" term="%22Khouri+MG%22">Khouri MG</searchLink>; Department of Medicine, Division of Cardiology, Duke University Hospital System, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Masri+A%22">Masri A</searchLink>; Division of Cardiovascular Medicine, Oregon Health and Sciences University, Portland, OR, USA.<br /><searchLink fieldCode="AU" term="%22Maurer+MS%22">Maurer MS</searchLink>; Columbia University Irving Medical Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Obici+L%22">Obici L</searchLink>; Amyloidosis Research and Treatment Centre, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.<br /><searchLink fieldCode="AU" term="%22Solomon+S%22">Solomon S</searchLink>; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Sperry+BW%22">Sperry BW</searchLink>; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.<br /><searchLink fieldCode="AU" term="%22Tahara+N%22">Tahara N</searchLink>; Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.<br /><searchLink fieldCode="AU" term="%22Waddington-Cruz+M%22">Waddington-Cruz M</searchLink>; Centro de Paramiloidose Antônio Rodrigues de Mello (CEPARM), Amyloidosis Center, University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; Amyloidosis Center, Complexo Hospitalar Américas- Samaritano-Vitória,  Barra da Tijuca, Rio de Janeiro, Brazil.<br /><searchLink fieldCode="AU" term="%22Conrad+T%22">Conrad T</searchLink>; Statistics, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Yang+Q%22">Yang Q</searchLink>; Ionis Pharmaceuticals, Carlsbad, CA, USA.<br /><searchLink fieldCode="AU" term="%22Chen+J%22">Chen J</searchLink>; Late-Stage Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MA, USA.<br /><searchLink fieldCode="AU" term="%22Tsimikas+S%22">Tsimikas S</searchLink>; Ionis Pharmaceuticals, Carlsbad, CA, USA.<br /><searchLink fieldCode="AU" term="%22Gillmore+JD%22">Gillmore JD</searchLink>; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London, United Kingdom. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100887595%22">European journal of heart failure</searchLink> [Eur J Heart Fail] 2026 May 30. <i>Date of Electronic Publication: </i>2026 May 30. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100887595 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1879-0844 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213889842%22">13889842 </searchLink><i>NLM ISO Abbreviation: </i>Eur J Heart Fail <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42217207 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1093/ejhf/xuag168 Languages: – Code: eng Text: English Titles: – TitleFull: Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersen. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Fontana M – PersonEntity: Name: NameFull: Ambardekar AV – PersonEntity: Name: NameFull: Cappelli F – PersonEntity: Name: NameFull: Cuddy SAM – PersonEntity: Name: NameFull: Davis MK – PersonEntity: Name: NameFull: Garcia-Pavia P – PersonEntity: Name: NameFull: Hanna M – PersonEntity: Name: NameFull: Khouri MG – PersonEntity: Name: NameFull: Masri A – PersonEntity: Name: NameFull: Maurer MS – PersonEntity: Name: NameFull: Obici L – PersonEntity: Name: NameFull: Solomon S – PersonEntity: Name: NameFull: Sperry BW – PersonEntity: Name: NameFull: Tahara N – PersonEntity: Name: NameFull: Waddington-Cruz M – PersonEntity: Name: NameFull: Conrad T – PersonEntity: Name: NameFull: Yang Q – PersonEntity: Name: NameFull: Chen J – PersonEntity: Name: NameFull: Tsimikas S – PersonEntity: Name: NameFull: Gillmore JD IsPartOfRelationships: – BibEntity: Dates: – D: 30 M: 05 Text: 2026 May 30 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1879-0844 Titles: – TitleFull: European journal of heart failure Type: main |
| ResultId | 1 |